Hospital Particular do Algarve – Gambelas Day Care Hospital is performing, for the first time in Portugal, adjuvant treatment with immunotherapy – Nivolumab (Opdivo®) – in an operated stage III melanoma patient.

This new indication (approved by the FDA since December 2017) is a big step forward in the treatment of this aggressive disease with a high likelihood of relapsing after surgery. In Europe, there was no standard care for adjuvant treatment after melanoma surgery.